Literature DB >> 11956064

Prolonged inflammatory response to acute Pseudomonas challenge in interleukin-10 knockout mice.

James F Chmiel1, Michael W Konstan, Aicha Saadane, Jeanne E Krenicky, H Lester Kirchner, Melvin Berger.   

Abstract

Cystic fibrosis (CF) lung disease is characterized by a neutrophilic infiltrate that is excessive relative to the burden of infection. Decreased interleukin-10 in CF airways may impair proper termination of inflammation, leading to persistence of neutrophils after acute infections have been cleared. This could explain reports of lung inflammation in the absence of bacteria in infants with CF. We evaluated the kinetics of inflammation after transient Pseudomonas aeruginosa challenge in IL-10 knockout (KO) and wild-type (WT) mice. Both types of mice cleared the infection by Day 6 (p > or = 0.29). However, IL-10 KO mice had more neutrophils in bronchoalveolar lavage fluid than did WT mice on Days 4 (p < 0.0001), 6 (p < 0.0001), and 8 (p = 0.042). IL-10 KO mice had high concentrations of proinflammatory cytokines in BAL on Days 2 and 4, with some cytokines detectable on Days 6 and 8, whereas cytokines in BAL from WT mice were greatest on Day 2 and undetectable by Day 4. Moreover, IL-10 KO mice failed to regenerate IkappaBalpha once degraded and subsequently had prolonged activation of NF-kappaB. These data suggest that IL-10 deficiency contributes to prolonged inflammatory responses early in CF, when infection may be transient.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11956064     DOI: 10.1164/ajrccm.165.8.2107051

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  23 in total

Review 1.  Innate immune responses to Pseudomonas aeruginosa infection.

Authors:  Elise G Lavoie; Tamding Wangdi; Barbara I Kazmierczak
Journal:  Microbes Infect       Date:  2011-08-02       Impact factor: 2.700

2.  Parthenolide inhibits IkappaB kinase, NF-kappaB activation, and inflammatory response in cystic fibrosis cells and mice.

Authors:  Aicha Saadane; Sophia Masters; Joseph DiDonato; Jingfeng Li; Melvin Berger
Journal:  Am J Respir Cell Mol Biol       Date:  2007-02-01       Impact factor: 6.914

Review 3.  Interleukin-10 and immunity against prokaryotic and eukaryotic intracellular pathogens.

Authors:  Joshua C Cyktor; Joanne Turner
Journal:  Infect Immun       Date:  2011-05-16       Impact factor: 3.441

Review 4.  Antibiotic and anti-inflammatory therapies for cystic fibrosis.

Authors:  James F Chmiel; Michael W Konstan; J Stuart Elborn
Journal:  Cold Spring Harb Perspect Med       Date:  2013-10-01       Impact factor: 6.915

5.  IL-27 Promotes Human Placenta-Derived Mesenchymal Stromal Cell Ability To Induce the Generation of CD4+IL-10+IFN-γ+ T Cells via the JAK/STAT Pathway in the Treatment of Experimental Graft-versus-Host Disease.

Authors:  Junzhu Yi; Zhenghua Chen; Fenghuang Xu; ZhuoYa Wang; Aiping Zhang; Tongshen Liu; Nannan Zhao; Yanlian Xiong; Guosheng Jiang; Junjie Ma; Xiying Luan
Journal:  J Immunol       Date:  2019-01-16       Impact factor: 5.422

Review 6.  Disease modifying genes in cystic fibrosis: therapeutic option or one-way road?

Authors:  Rainer Büscher; Hartmut Grasemann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-10-11       Impact factor: 3.000

Review 7.  The role of inflammation in the pathophysiology of CF lung disease.

Authors:  James F Chmiel; Melvin Berger; Michael W Konstan
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

8.  IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice.

Authors:  Patricia J Dubin; Jay K Kolls
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-10-27       Impact factor: 5.464

Review 9.  Chronic inflammation in the cystic fibrosis lung: alterations in inter- and intracellular signaling.

Authors:  David Nichols; James Chmiel; Melvin Berger
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

Review 10.  Anti-inflammatory therapies for cystic fibrosis-related lung disease.

Authors:  David P Nichols; Michael W Konstan; James F Chmiel
Journal:  Clin Rev Allergy Immunol       Date:  2008-12       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.